Pierre Fabre, Forest Laboratories report positive Phase III MDD study data
The study showed that levomilnacipran considerably reduced depression symptoms in MDD patients compared to placebo and further analyses of the data are ongoing. The companies expect to file
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.